Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients ...

pen fill cartridge Novolog Mix 70/30 pen fill cartridge (Novo Nordisk) 14 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin ...

Ellison says the settlement requires Novo Nordisk to provide insulin products—including Novolog, Tresiba ... prescription (3 vials or 2 packs of pens) for customers paying with cash.

The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine), Novo Nordisk's Novolog (insulin aspart ... than $55 for a box of five pen cartridges – which Civica ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Novo Nordisk's Novolog, and Lilly's Humalog – by 2024. The company said its products will cost no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 per ...